Mucopolysaccharidosis VII Disease Monitoring Program



Status:Recruiting
Conditions:Metabolic
Therapuetic Areas:Pharmacology / Toxicology
Healthy:No
Age Range:Any
Updated:3/21/2019
Start Date:January 29, 2018
End Date:May 2033
Contact:Patients Contact: Patient Advocacy
Email:patientadvocacy@ultragenyx.com
Phone:1-415-483-8800

Use our guide to learn which trials are right for you!

Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)

The objectives of this study are to characterize MPS VII disease presentation and progression
and assess long-term effectiveness and safety, including hypersensitivity reactions and
immunogenicity of vestronidase alfa.

The Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP) is a global,
prospective, multicenter, longitudinal protocol designed to characterize MPS VII disease
presentation and progression, assess long-term effectiveness and safety of vestronidase alfa,
including hypersensitivity reactions and immunogenicity , as well as prospectively
investigate longitudinal change across biomarker(s), clinical assessments, and patient/
caregiver-reported outcome measures in a representative population. The aim of this DMP is to
collect data on patients with MPS VII to provide a comprehensive dataset on the clinical
presentation, heterogeneity, and disease progression, and meaningful standardized ICH
GCP-quality data collected in-clinic across multiple sites globally. The DMP is not a
randomized study and both treated and untreated patients will be enrolled.

Inclusion Criteria:

- Diagnosis of MPS VII based on laboratory diagnosis, including either enzymatic or
mutation analysis.

- Willing and able to provide written informed consent or, in the case of patients under
the age of 18 (or 16 years, depending on the region) or patients >18 years of age who
have cognitive deficiencies, provide written assent (if required) and written informed
consent by a legally authorized representative after the nature of the DMP has been
explained, and prior to any research-related procedures.

- Willing to comply with DMP visit schedule.

Exclusion Criteria:

- Concurrent enrollment in an Ultragenyx-sponsored clinical trial.

- Participation in any other pharmaceutical company-sponsored interventional clinical
trial unless approved by Ultragenyx.
We found this trial at
2
sites
550 1st Ave
New York, New York 10016
(212) 263-7300
New York University Langone Medical Center NYU NYU Langone Medical Center, a world-class, patient-centered, integrated,...
?
mi
from
New York, NY
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials